RDPAC药品推广行为准则 - IFPMA

IFPMA药品推广行为准则
(2012)-- 序言
推进医学知识和改善全球公共
卫生有赖于整个医学界在信息分享
方面的互动交流-从研究人员到从
业医师、护士到患者-而这些互动
交流活动的关键就在于其道德上的
正直性。从根本上讲,公众必须对
医生开具处方这一行为是道德的和
为患者着想的这一点充满信心。
在这些互动交流中,政府、
医 疗 卫 生 行 业 及 患 者 对 制 药 企
业 , 无 论 其 在 世 界 任 何 地 方 经
营,系以道德的和专业的方式从
事经营活动是否有信心是极其重
要的。而以高道德标准从业不仅应
适用于药品推广活动,其应更广泛
地适用于所有与医疗卫生行业的互
动交流活动。这就是我们,国际制
药企业协会联盟代表研发制药行
业在最新修订的行为准则中所做
的承诺。
该行为准则自1981作为行业
在全球范围自律的基础性文件以
Foreword of IFPMA Code
of Practice 2012
Advancing medical knowledge and
improving global public health depend
on information-sharing interactions
by the entire medical community
- from researcher to attending
physician and nurse to patient – and
integrity is essential to these exchanges.
Fundamentally, there must
always be confidence that prescription
decisions are made on an ethical
and patient-focused basis.
In these interactions, it is essential that
governments, the healthcare community
and patients are confident that
pharmaceutical companies, wherever
they operate in the world, act in an
ethical and professional manner. Such
ethical practices should apply not
only to the promotion of medicines but
more broadly to all interactions with
the healthcare community. This is the
commitment that we, the International
Federation of Pharmaceutical Manufacturers
and Associations (IFPMA)
representing the research-based
pharmaceutical industry, make in our
recently-revised Code of Practice.
Since its initial adoption in 1981 as the
foundation of a global self-regulatory
approach, the Code has been regu-
3
研
制
开
发
制
药
企
业
协
会